We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    flot6
Previous Study | Return to List | Next Study

FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (PETRARCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02581462
Recruitment Status : Recruiting
First Posted : October 21, 2015
Last Update Posted : January 9, 2018
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of Herceptin and pertuzumab in combination with FLOT in the perioperative treatment of resectable HER-2 positive adenocarcinoma of the stomach or GEJ.

Condition or disease Intervention/treatment Phase
Stomach Cancer Gastroesophageal Junction Cancer Drug: FLOT alone Biological: FLOT + Herceptin/Pertuzumab Phase 2 Phase 3

Detailed Description:

This is a multicenter, randomized, controlled, open-label study including patients with locally advanced adenocarcinoma of the stomach and GEJ scheduled to receive perioperative chemotherapy. According to centrally assessed HER-2 status: Patients with HER-2 positive tumors will receive FLOT +/- Herceptin / pertuzumab.

The scope of the phase II portion of the trial is to evaluate pathological response rates of either regimen assessed by a centralized pathology and define safety and tolerability.

Patients with locally advanced esophagogastric adenocarcinoma (i.e. cT2 any N or any T N-positive) with exclusion of distant metastases will be included in this trial.

Patients will be stratified by age (18-69 vs. ≥ 70), tumor site (GEJ vs. gastric) and clinical stage (T1/2 vs. 3/4 and N- vs. N+) and randomized 1:1 to receive either FLOT (Arm A) or FLOT/Herceptin/pertuzumab (Arm B).

Arm A (control group) Patients randomized to Arm A will receive 4 pre-operative treatments of FLOT (Docetaxel 50 mg/m², iv over 2 h; Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h; Leucovorin 200 mg/m² in 250 ml NaCl 0.9 %, iv over 1 h; 5-FU 2600 mg/m², iv over 24 h) on d1, d15, d29, d43 of the preoperative treatment phase. Surgery is recommended to occur 4 weeks after last FLOT (4 weeks after d43 = day 71). Patients will receive 4 additional post-operative treatments of FLOT on d1, d15, d29, and d43 of the post-operative treatment phase. Post-operative treatment should start 6 to 8 weeks, but at maximum 12 weeks after surgery.

Arm B (Herceptin/pertuzumab group) Patients randomized to Arm B will receive the FLOT regimen identical to Arm A as described above in conjunction with three-weekly Herceptin at 8mg/kg initial dose (Day 1, loading dose) followed by subsequent doses of Herceptin at 6mg/kg on d22 and d43 and pertuzumab at 840mg on d1, d22, and d43. Surgery is recommended to occur 4 weeks after last FLOT/Herceptin/pertuzumab dose (4 weeks after d43 = day 71). Patients will receive 3 additional doses of Herceptin and pertuzumab on d1, d22, and d43 of the post-operative treatment phase, together with the postoperative chemotherapy. Moreover, patients will receive 11 additional doses of Herceptin and pertuzumab after the end of post-operative FLOT.

In both of the arms, tumor assessments (CT or MRI) are performed before randomization and prior to surgery and then every 3 months thereafter until progression/relapse, death or end of follow-up.

During treatment, clinical visits (blood cell counts, detection of toxicity) occur prior to every treatment dose. Safety of FLOT/Herceptin/pertuzumab will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs) reported.


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 404 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of Adenocarcinoma of the Stomach and Gastroesophageal Junction Expressing HER-2. A Phase II/III Trial of the AIO.
Study Start Date : May 2016
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Pertuzumab
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: FLOT alone
Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
Drug: FLOT alone

Pre-operative therapy:

  • Docetaxel 50 mg/m², d1, d15, d29, d43
  • Oxaliplatin 85 mg/m², d1, d15, d29, d43
  • Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
  • 5-FU 2600 mg/m², d1, d15, d29, d43

Surgery is recommended to be scheduled 4 weeks after d43.

Post-operative therapy (start 6 to 8 weeks after surgery):

  • Docetaxel 50 mg/m², d1, d15, d29, d43
  • Oxaliplatin 85 mg/m², d1, d15, d29, d43
  • Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
  • 5-FU 2600 mg/m², d1, d15, d29, d43
Experimental: FLOT + Herceptin/Pertuzumab
Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab
Biological: FLOT + Herceptin/Pertuzumab

Pre-operative therapy:

  • Herceptin 8/6 mg/kg, d1, d22, d43
  • Pertuzumab 840 mg, d1, d22, d43
  • Docetaxel 50 mg/m², d1, d15, d29, d43
  • Oxaliplatin 85 mg/m², d1, d15, d29, d43
  • Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
  • 5-FU 2600 mg/m², d1, d15, d29, d43

Surgery is recommended to be scheduled 4 weeks after d43.

Post-operative therapy (start 6 to 8 weeks after surgery):

  • Herceptin 8/6 mg/kg, d1, d22, d43
  • Pertuzumab 840 mg, d1, d22, d43
  • Docetaxel 50 mg/m², d1, d15, d29, d43
  • Oxaliplatin 85 mg/m², d1, d15, d29, d43
  • Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
  • 5-FU 2600 mg/m², d1, d15, d29, d43.


Outcome Measures

Primary Outcome Measures :
  1. PhaseII: Rate of pathological complete response [ Time Frame: 3 years ]
  2. Phase III: Median Progression Free Survival [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Phase II/III: R0 resection rate [ Time Frame: 75 days ]
  2. Phase II: Median Progression Free Survival (PFS) [ Time Frame: 3 years ]
  3. Phase II/III: Median Overall Survival [ Time Frame: 3/5 years ]
  4. Phase II: PK Analysis [ Time Frame: 3 years ]
  5. Phase II/III: Subgroup analyses: pathological response according to HER-2 status HER-2 IHC 3+ vs. other cases [ Time Frame: 3/5 years ]
  6. Phase II/III: Subgroup analyses: PFS according to HER-2 status HER-2 IHC 3+ vs. other cases [ Time Frame: 3/5 years ]
  7. Phase II/III: Subgroup analyses: OS according to HER-2 status HER-2 IHC 3+ vs. other cases [ Time Frame: 3/5 years ]
  8. Phase III: Pathological Response Rates [ Time Frame: 5 years ]
  9. Phase III: PFS rates [ Time Frame: 3 and 5 years ]
  10. Phase III: OS rates [ Time Frame: 3 and 5 years ]
  11. Phase III: Median OS [ Time Frame: 5 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed adenocarcinoma of the GEJ (type I-III) or the stomach (uT2, uT3, uT4, any N category, M0), or any T N+ M0 patient, with the following specifications:

    • Medical and technical operability
    • Centralized detection of either an adenocarcinoma with HER-2 3+ (IHC) or HER-2 2+ (IHC) with amplification proven by FISH, SISH or CISH
  2. No preceding cytotoxic or targeted therapy
  3. No prior partial or complete tumor resection
  4. Exclusion of the infiltration of any adjacent organs or structures by CT or MRI
  5. Exclusion of distant metastasis by CT or MRI of thorax and abdomen, and bone scan (if osseous lesions are suspected due to clinical signs)
  6. Female and male patients ≥ 18 years. Patients in reproductive age must be willing to use adequate contraception during the study and for 7 months after the end of pertuzumab and Herceptin treatment (Appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)). Female patients with childbearing potential need to have a negative pregnancy test within 7 days before study start.
  7. ECOG ≤ 2
  8. Laparoscopic exclusion of peritoneal carcinomatosis, if suspected clinically
  9. Adequate haematological, hepatic and renal function parameters:

    • Leukocytes ≥ 3.000/mm³, platelets ≥ 100.000/mm3
    • Serum creatinine ≤ 1.5 x upper limit of normal, or GFR > 40 ml/min
    • Bilirubin ≤ 1.5 x upper limit of normal, AST and ALT ≤ 3.5 x upper limit of normal, alkaline phosphatase ≤ 6 x upper limit of normal
  10. LVEF value > 55 %, as assessed by echocardiography
  11. Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures

Exclusion Criteria:

  1. Patients with involved retroperitoneal (e.g. para-aortal, paracaval or interaortocaval lymph nodes) or mesenterial lymph nodes (distant metastasis!)
  2. Known hypersensitivity against Herceptin, pertuzumab, 5-FU, leucovorin, oxaliplatin, or docetaxel
  3. Other known contraindications against Herceptin, pertuzumab, 5-FU, leucovorin, oxaliplatin, or docetaxel
  4. Documented history of congestive heart failure of any NYHA, myocardial infarction within the past 6 months before the first dose of study treatment
  5. Clinically significant valvular defect , history of poorly controlled arterial hypertension (systolic blood pressure > 180 mmHG or diastolic blood pressure > 100 mmHg) or uncontrollable high-risk cardiac arrhythmia (i.e tachycardia with a heart rate > 100/min at rest), significant ventricular arrhythmia (ventricular tachycardia) or higher grade atrioventricular-block (second degree AV-block Type 2 (Mobitz2) or third degree AV-block)
  6. Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix
  7. Known brain metastases
  8. Other severe internal disease or acute infection
  9. Peripheral polyneuropathy ≥ NCI Grade II
  10. Chronic inflammatory bowel disease
  11. Clinically significant active GI bleeding
  12. On-treatment participation in another clinical study in the period 30 days prior to inclusion and during the study
  13. Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
  14. Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4)
  15. Any other concurrent antineoplastic treatment including irradiation
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02581462


Contacts
Contact: Salah-Eddin Al-Batran, Prof. Dr. +49697601 ext 4420 albatran@khnw.de
Contact: Gerrit zur Hausen, Dr. +49697601 ext 4562 zurhausen.gerrit@khnw.de

Locations
Germany
Institute for Clinical Cancer Research Krankenhaus Nordwest Recruiting
Frankfurt, Germany, 60488
Contact: Salah-Eddin Al-Batran, Prof    +496976014420      
Contact: Gerrit zur Hausen, Dr.    +496976014562      
Sponsors and Collaborators
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Trium Analysis Online GmbH
Investigators
Principal Investigator: Ralf-Dieter Hofheinz, Prof. Dr. Universitätsmedizin Mannheim
More Information

Responsible Party: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
ClinicalTrials.gov Identifier: NCT02581462     History of Changes
Other Study ID Numbers: ML29452/PETRARCA/FLOT6
First Posted: October 21, 2015    Key Record Dates
Last Update Posted: January 9, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Pertuzumab
Trastuzumab
Antineoplastic Agents